EyePoint Pharmaceuticals, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q2 2011 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
EyePoint Pharmaceuticals, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q2 2011 to Q4 2023.
  • EyePoint Pharmaceuticals, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $146M, a 17.3% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $146M +$21.6M +17.3% Dec 31, 2023 10-K 2024-03-08
Q4 2022 $125M +$26.1M +26.4% Dec 31, 2022 10-K 2024-03-08
Q4 2021 $98.7M +$15.8M +19.1% Dec 31, 2021 10-K 2023-03-10
Q4 2020 $82.9M +$13M +18.6% Dec 31, 2020 10-K 2022-03-14
Q4 2019 $69.9M +$15.6M +28.8% Dec 31, 2019 10-K 2021-03-12
Q4 2018 $54.3M Dec 31, 2018 10-K 2020-03-16
Q2 2018 $47.1M +$765K +1.65% Jun 30, 2018 10-KT 2019-03-18
Q2 2017 $46.4M +$7.49M +19.3% Jun 30, 2017 10-KT 2019-03-18
Q2 2016 $38.9M +$6.79M +21.2% Jun 30, 2016 10-K 2017-09-13
Q2 2015 $32.1M -$3.57M -10% Jun 30, 2015 10-K 2016-09-13
Q2 2014 $35.6M +$4.62M +14.9% Jun 30, 2014 10-K 2015-09-10
Q2 2013 $31M +$2.94M +10.5% Jun 30, 2013 10-K 2014-09-11
Q2 2012 $28.1M +$7.5M +36.4% Jun 30, 2012 10-K 2013-09-27
Q2 2011 $20.6M Jun 30, 2011 10-K 2012-09-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.